BR112021019703A2 - Compostos heterocíclicos e usos dos mesmos - Google Patents

Compostos heterocíclicos e usos dos mesmos

Info

Publication number
BR112021019703A2
BR112021019703A2 BR112021019703A BR112021019703A BR112021019703A2 BR 112021019703 A2 BR112021019703 A2 BR 112021019703A2 BR 112021019703 A BR112021019703 A BR 112021019703A BR 112021019703 A BR112021019703 A BR 112021019703A BR 112021019703 A2 BR112021019703 A2 BR 112021019703A2
Authority
BR
Brazil
Prior art keywords
heterocyclic compounds
compounds
find
oncology
therapeutic agents
Prior art date
Application number
BR112021019703A
Other languages
English (en)
Inventor
Brahmam Pujala
Deepak Palve
Jayakanth Kankanala
Puja Jaiswal
Sanjeev Soni
Sarvajit Chakravarty
Minh Pham Son
Varun Kumar
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of BR112021019703A2 publication Critical patent/BR112021019703A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos heterocíclicos e usos dos mesmos. referência cruzada a pedido relacionado. a presente invenção refere-se a compostos heterocíclicos como inibidores de wee1. os compostos podem encontrar uso como agentes terapêuticos para o tratamento de doenças e podem encontrar particular uso na oncologia.
BR112021019703A 2019-04-09 2020-04-08 Compostos heterocíclicos e usos dos mesmos BR112021019703A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831665P 2019-04-09 2019-04-09
PCT/US2020/027297 WO2020210375A1 (en) 2019-04-09 2020-04-08 Heterocyclic compounds and uses thereof

Publications (1)

Publication Number Publication Date
BR112021019703A2 true BR112021019703A2 (pt) 2021-12-14

Family

ID=72748693

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019703A BR112021019703A2 (pt) 2019-04-09 2020-04-08 Compostos heterocíclicos e usos dos mesmos

Country Status (14)

Country Link
US (2) US11332473B2 (pt)
EP (1) EP3952877A4 (pt)
JP (1) JP2022526831A (pt)
KR (1) KR20210150476A (pt)
CN (1) CN113939296A (pt)
AU (1) AU2020271837A1 (pt)
BR (1) BR112021019703A2 (pt)
CA (1) CA3136492A1 (pt)
CL (1) CL2021002521A1 (pt)
EA (1) EA202192746A1 (pt)
IL (1) IL287026A (pt)
MX (1) MX2021012418A (pt)
SG (1) SG11202110615TA (pt)
WO (1) WO2020210375A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2023280180A1 (zh) * 2021-07-05 2023-01-12 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
CN117940430A (zh) * 2021-09-22 2024-04-26 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003201885B2 (en) 2002-01-18 2007-08-30 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyrimidine derivatives
KR101099409B1 (ko) 2003-06-06 2011-12-27 아렉시스 악티에볼라그 피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의융합된 헤테로사이클 화합물의 용도
EP1812429A4 (en) 2004-09-29 2010-07-21 Portola Pharm Inc SUBSTITUTED 2H-1,3-BENZOXAZIN-4 (3H) -ONE
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
SI2168966T1 (sl) 2007-06-15 2017-03-31 Msd K.K. Derivat biciklo anilina
US8329711B2 (en) * 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EP2376494A4 (en) 2008-12-12 2012-07-11 Msd Kk DIHYDROPYRIMIDOPIRYMIDINE DERIVATIVES
WO2011034743A1 (en) 2009-09-15 2011-03-24 Merck Sharp & Dohme Corp. Preparation of crystalline forms of dihydropyrazolopyrimidinone
WO2013013031A1 (en) 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
CA2851640A1 (en) 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
CN104271576A (zh) 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
AU2016344040B2 (en) 2015-11-01 2020-12-10 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
GB201612095D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
KR102030886B1 (ko) 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AU2017359844B2 (en) 2016-11-16 2021-09-30 Impact Therapeutics (Shanghai), Inc 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6H)-ketone compound
ES2902050T3 (es) 2017-01-23 2022-03-24 Shijiazhuang Sagacity New Drug Dev Co Ltd Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
GB201703881D0 (en) 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
CN108623615B (zh) * 2017-03-23 2022-12-13 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
EP3600247A1 (en) 2017-03-31 2020-02-05 Seattle Genetics, Inc. Combinations of chk1- and wee1 - inhibitors
CN110914277B (zh) 2017-07-10 2022-08-09 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
MX2020001235A (es) * 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
WO2019037678A1 (zh) 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
WO2019096322A1 (zh) 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN111315747B (zh) 2018-01-05 2023-05-02 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11479555B2 (en) * 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
WO2019169065A2 (en) 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
MX2020009372A (es) * 2018-03-09 2020-10-14 Recurium Ip Holdings Llc 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
US20220169646A1 (en) 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3952878A4 (en) 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
US20220162229A1 (en) 2019-04-09 2022-05-26 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3952875A4 (en) 2019-04-09 2022-12-28 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF

Also Published As

Publication number Publication date
SG11202110615TA (en) 2021-10-28
US20230118115A1 (en) 2023-04-20
JP2022526831A (ja) 2022-05-26
KR20210150476A (ko) 2021-12-10
MX2021012418A (es) 2021-11-12
IL287026A (en) 2021-12-01
EA202192746A1 (ru) 2021-12-29
CA3136492A1 (en) 2020-10-15
CL2021002521A1 (es) 2022-04-29
US20200325142A1 (en) 2020-10-15
WO2020210375A1 (en) 2020-10-15
EP3952877A4 (en) 2022-12-14
CN113939296A (zh) 2022-01-14
US11332473B2 (en) 2022-05-17
EP3952877A1 (en) 2022-02-16
AU2020271837A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
BR112021019703A2 (pt) Compostos heterocíclicos e usos dos mesmos
CU20210029A7 (es) Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
CO2017011851A2 (es) Compuestos novedosos
BR112015023760A2 (pt) compostos e composições terapêuticas
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112017024555A2 (pt) moduladores de ccr2
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
BR112014009006B8 (pt) Compostos heterocíclicos e métodos de uso dos mesmos
BR112021026668A2 (pt) Compostos heterocíclicos como inibidores de bet
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
BR112015030515A2 (pt) intensificadores de inibidores de homólogo 2 de zeste

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]